AI assistant
Sending…
Passage BIO, Inc. — Director's Dealing 2023
Apr 6, 2023
34849_dirs_2023-04-05_56490885-01d9-4b5a-9a65-af007eb4ddaf.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Passage BIO, Inc. (PASG)
CIK: 0001787297
Period of Report: 2023-03-15
Reporting Person: Fotopoulos Alexandros (Chief Technical Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-03-15 | Employee Stock Option (right to buy) | $1.08 | A | 175000 | Acquired | 2033-03-14 | Common Stock (175000) | Direct |
Footnotes
F1: The stock option vests as of 1/48 of the total shares monthly beginning on April 15, 2023 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
More from Passage BIO, Inc.
Regulatory Filings
2026
May 27
Regulatory Filings
2026
May 26
Interim / Quarterly Report
2026
May 12
Regulatory Filings
2026
Apr 28
Regulatory Filings
2026
Apr 20
Annual Report
2026
Apr 7
Proxy Solicitation & Information Statement
2026
Apr 7
Director's Dealing
2026
Mar 18
Annual Report
2026
Mar 3
Regulatory Filings
2026
Mar 3